You are here

  • Home
  • Archive
  • Volume 19, Issue 6
  • Lactobacillus reuteri is an effective option for the prevention of diarrhoea in preschool children but may not be cost-effective in all settings

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Lactobacillus reuteri is an effective option for the prevention of diarrhoea in preschool children but may not be cost-effective in all settings
  1. Yvan Vandenplas
  1. Department of Pediatrics, Universitair Ziekenhuis Brussel, Brussels, Belgium
  1. Correspondence to : Dr Yvan Vandenplas, Department of Pediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium; yvan.vandenplas{at}uzbrussel.be

https://doi.org/10.1136/ebmed-2014-110039

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Gutierrez-Castrellon P, Lopez-Velazquez G, Diaz-Garcia L, et al. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics 2014;133:e904–9.OpenUrlAbstract/FREE Full Text

    Context

    Diarrhoea remains a serious health burden for young children worldwide, with a high incidence of morbidity and mortality in the developing world. Oral rehydration solution dramatically improves outcomes, but does not influence the duration of diarrhoea. Selected probiotic strains have been shown to reduce the duration of acute gastroenteritis by around 24 h.1 Gutierrez-Castrellon and colleagues set out to evaluate whether probiotics administered in prevention could reduce the incidence of infectious gastroenteritis.

    Methods

    Much attention has been paid to the study design by the authors. The probiotics and placebo arms were identical, except for the presence of the probiotic Lactobacillus reuteri, given daily over 12 weeks to …

    View Full Text

    Footnotes

    • Competing interests YV is a consultant for Biocodex and United Pharmaceuticals.

    • Provenance and peer review Not commissioned; internally peer reviewed.